# Missouri

Type: government

Source: Biotech Intelligence Brief — https://getbiobrief.com/entity/missouri-government
Canonical HTML page: https://getbiobrief.com/entity/missouri-government

## Timeline

- **2026-03-21**: Public Notification — Official announcement made to the public and healthcare providers regarding state status.
- **2026-03-20**: Initial Diagnosis — Missouri DHSS confirms two positive test results for mpox.
- **2026-03-20**: Contact Tracing Launch — Public health officials begin identifying close contacts of the two patients.
- **2026-03-12**: Missouri Pause Request — DOJ files a request in federal court to pause the Missouri-led lawsuit citing an ongoing FDA review.
- **2026-03-11**: Hawley Federal Bill — Senator Josh Hawley introduces a bill in the Senate to ban mifepristone nationwide.
- **2026-01-15**: Louisiana Pause Request — DOJ asks Louisiana to pause its separate lawsuit; request is rejected by AG Liz Murrill.
- **2025-10-01**: Missouri Lawsuit Filed — Missouri, Kansas, and Idaho file suit against the FDA to restrict mifepristone access.

## Recent coverage (2 stories)

### Missouri Reports First Two Cases of Mpox; DHSS Initiates Contact Tracing
2026-03-21 01:20:35 · Sentiment: Neutral · Impact: 5/10 · Sources: 2

The Missouri Department of Health and Senior Services has confirmed the state's first two cases of mpox (monkeypox), marking the virus's official entry into the state. Health officials have launched immediate contact tracing efforts to contain potential community spread and are coordinating with federal partners for vaccine distribution.
Full story: https://getbiobrief.com/story/missouri-first-mpox-cases-dhss-response

### DOJ Seeks Pause in Missouri Mifepristone Suit Amid FDA Review Strategy
2026-03-13 00:35:09 · Sentiment: Bearish · Impact: 8/10 · Sources: 2

The Department of Justice has requested a federal court to pause a multi-state lawsuit against the FDA regarding the abortion pill mifepristone. The move suggests a strategic effort to allow the FDA to conduct its own internal review of the drug's safety and distribution protocols.
Full story: https://getbiobrief.com/story/doj-missouri-mifepristone-lawsuit-pause

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://getbiobrief.com/guides/methodology for the full editorial methodology.